Praxis Precision Medicines Reports Promising Drug Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 06 2026
0mins
Should l Buy PRAX?
Source: seekingalpha
- Clinical Trial Results: Praxis Precision Medicines reported a 77% placebo-adjusted seizure reduction for elsunersen in the EMBRAVE Part A trial, indicating significant efficacy in treating early-onset SCN2A developmental and epileptic encephalopathy.
- Positive Patient Response: 57% of patients remained seizure-free for at least 28 days post-treatment, and results were sustained for up to one year in the open-label extension, demonstrating the drug's long-term efficacy and safety.
- Good Safety Profile: No severe drug-related adverse events were reported during the trial, with most treatment-emergent adverse events being mild to moderate, indicating a high safety profile for the drug.
- Positive Market Reaction: Following the promising trial results, Praxis Precision Medicines saw its stock rise approximately 5% in premarket trading, reflecting investor optimism about the company's future prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRAX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRAX
Wall Street analysts forecast PRAX stock price to rise
15 Analyst Rating
14 Buy
0 Hold
1 Sell
Strong Buy
Current: 342.500
Low
95.00
Averages
456.71
High
843.00
Current: 342.500
Low
95.00
Averages
456.71
High
843.00
About PRAX
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Company’s product candidates include ulixacaltamide, vormatrigine, relutrigine, PRAX-080, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Praxis Precision Medicines FDA Accepts New Drug Application for Ulixacaltamide
- FDA Application Progress: Praxis Precision Medicines' new drug application for ulixacaltamide HCl has been accepted for review by the FDA, marking a significant advancement in addressing essential tremor, a common movement disorder affecting nearly 7 million Americans, which is expected to enhance the company's market competitiveness.
- Clinical Trial Success: The application is supported by data from the company's Essential3 Phase 3 clinical trials, where two pivotal studies met their primary endpoints, demonstrating statistically and clinically significant results for ulixacaltamide in adults with essential tremor, further strengthening its market outlook.
- Target Action Date: The FDA has set January 29, 2027, as the target action date for the new drug application and has not indicated plans for an advisory committee meeting, which could expedite the approval process and boost investor confidence.
- Positive Market Reaction: Praxis's stock rose approximately 6% in premarket trading, reflecting investor optimism regarding the FDA's acceptance of the application, signaling potential future growth for the company.
See More
Praxis Precision Medicines' NDA for Ulixacaltamide Accepted by FDA
- FDA Review Acceptance: Praxis Precision Medicines announced that its New Drug Application (NDA) for ulixacaltamide HCl for treating essential tremor in adults has been accepted for review by the FDA, marking a significant advancement in the company's therapeutic pipeline.
- Key Timeline: The FDA has set a target action date of January 29, 2027, under the Prescription Drug User Fee Act (PDUFA), indicating that the company will face a critical regulatory review phase in its development plans over the coming years.
- Clinical Trial Support: The NDA submission is backed by positive results from the Essential3 Phase 3 clinical program, which included two concurrently enrolled pivotal studies demonstrating statistically and clinically significant efficacy, laying a solid foundation for the drug's market potential.
- Good Safety Profile: Ulixacaltamide was generally well tolerated in clinical trials, with a safety profile consistent with previous studies and no drug-related serious adverse events reported, enhancing the likelihood of FDA approval.
See More
Praxis Receives FDA Review Acceptance for Ulixacaltamide NDA
- FDA Review Progress: Praxis Precision Medicines announced that its New Drug Application for ulixacaltamide HCl for treating essential tremor in adults has been accepted for review by the FDA, with a target action date set for January 29, 2027, marking a significant milestone in the company's CNS drug development.
- Clinical Trial Support: The NDA is supported by positive results from the Essential3 Phase 3 clinical trials, which demonstrated statistically and clinically significant efficacy of ulixacaltamide in treating essential tremor, further enhancing its market potential.
- Good Safety Profile: Ulixacaltamide exhibited good tolerability in clinical trials, with a safety profile consistent with previous studies and no drug-related serious adverse events, laying a solid foundation for its future commercialization.
- Breakthrough Therapy Designation: The drug received Breakthrough Therapy Designation from the FDA in December 2025, highlighting its innovation and market demand in treating essential tremor, as Praxis continues to collaborate with the FDA in preparation for its commercial launch.
See More
PRAXIS PRECISION MEDICINES INC: RAYMOND JAMES BEGINS COVERAGE WITH A STRONG BUY RATING AND A TARGET PRICE OF $815
Company Overview: Praxis Precision Medicines is highlighted for its strong buy rating, indicating positive investor sentiment and confidence in the company's future performance.
Target Price: The target price for Praxis Precision Medicines is set at $815, suggesting significant potential for growth based on current market evaluations.
See More
Praxis Precision Medicines Reports Promising Drug Results
- Clinical Trial Results: Praxis Precision Medicines reported a 77% placebo-adjusted seizure reduction for elsunersen in the EMBRAVE Part A trial, indicating significant efficacy in treating early-onset SCN2A developmental and epileptic encephalopathy.
- Positive Patient Response: 57% of patients remained seizure-free for at least 28 days post-treatment, and results were sustained for up to one year in the open-label extension, demonstrating the drug's long-term efficacy and safety.
- Good Safety Profile: No severe drug-related adverse events were reported during the trial, with most treatment-emergent adverse events being mild to moderate, indicating a high safety profile for the drug.
- Positive Market Reaction: Following the promising trial results, Praxis Precision Medicines saw its stock rise approximately 5% in premarket trading, reflecting investor optimism about the company's future prospects.
See More
Praxis Receives FDA Priority Review for Relutrigine
- FDA Review Progress: Praxis Precision Medicines announced that its New Drug Application (NDA) has been accepted for priority review by the FDA, with a target action date of September 27, 2026, marking a significant milestone in the company's evolution towards commercialization, as approval would make it the first disease-modifying therapy for SCN2A and SCN8A developmental epileptic encephalopathies.
- Clinical Trial Results: The NDA is supported by positive results from the EMBOLD study, which was stopped early for efficacy, demonstrating significant therapeutic effects of relutrigine in patients with severe epilepsy, potentially improving their quality of life.
- Drug Designations: Relutrigine has received Orphan Drug, Rare Pediatric Disease, and Breakthrough Therapy designations from the FDA, and if approved, it will be eligible for a Pediatric Review Voucher, enhancing its competitive position in the market.
- Future Research Plans: The drug is also being investigated in the EMERALD trial for broader DEEs, expected to be completed by the end of 2026, showcasing Praxis's ongoing innovation and commitment in the epilepsy treatment space.
See More
Praxis Precision Medicines FDA Accepts New Drug Application for Ulixacaltamide
- FDA Application Progress: Praxis Precision Medicines' new drug application for ulixacaltamide HCl has been accepted for review by the FDA, marking a significant advancement in addressing essential tremor, a common movement disorder affecting nearly 7 million Americans, which is expected to enhance the company's market competitiveness.
- Clinical Trial Success: The application is supported by data from the company's Essential3 Phase 3 clinical trials, where two pivotal studies met their primary endpoints, demonstrating statistically and clinically significant results for ulixacaltamide in adults with essential tremor, further strengthening its market outlook.
- Target Action Date: The FDA has set January 29, 2027, as the target action date for the new drug application and has not indicated plans for an advisory committee meeting, which could expedite the approval process and boost investor confidence.
- Positive Market Reaction: Praxis's stock rose approximately 6% in premarket trading, reflecting investor optimism regarding the FDA's acceptance of the application, signaling potential future growth for the company.
See More
Praxis Precision Medicines' NDA for Ulixacaltamide Accepted by FDA
- FDA Review Acceptance: Praxis Precision Medicines announced that its New Drug Application (NDA) for ulixacaltamide HCl for treating essential tremor in adults has been accepted for review by the FDA, marking a significant advancement in the company's therapeutic pipeline.
- Key Timeline: The FDA has set a target action date of January 29, 2027, under the Prescription Drug User Fee Act (PDUFA), indicating that the company will face a critical regulatory review phase in its development plans over the coming years.
- Clinical Trial Support: The NDA submission is backed by positive results from the Essential3 Phase 3 clinical program, which included two concurrently enrolled pivotal studies demonstrating statistically and clinically significant efficacy, laying a solid foundation for the drug's market potential.
- Good Safety Profile: Ulixacaltamide was generally well tolerated in clinical trials, with a safety profile consistent with previous studies and no drug-related serious adverse events reported, enhancing the likelihood of FDA approval.
See More
Praxis Receives FDA Review Acceptance for Ulixacaltamide NDA
- FDA Review Progress: Praxis Precision Medicines announced that its New Drug Application for ulixacaltamide HCl for treating essential tremor in adults has been accepted for review by the FDA, with a target action date set for January 29, 2027, marking a significant milestone in the company's CNS drug development.
- Clinical Trial Support: The NDA is supported by positive results from the Essential3 Phase 3 clinical trials, which demonstrated statistically and clinically significant efficacy of ulixacaltamide in treating essential tremor, further enhancing its market potential.
- Good Safety Profile: Ulixacaltamide exhibited good tolerability in clinical trials, with a safety profile consistent with previous studies and no drug-related serious adverse events, laying a solid foundation for its future commercialization.
- Breakthrough Therapy Designation: The drug received Breakthrough Therapy Designation from the FDA in December 2025, highlighting its innovation and market demand in treating essential tremor, as Praxis continues to collaborate with the FDA in preparation for its commercial launch.
See More
PRAXIS PRECISION MEDICINES INC: RAYMOND JAMES BEGINS COVERAGE WITH A STRONG BUY RATING AND A TARGET PRICE OF $815
Company Overview: Praxis Precision Medicines is highlighted for its strong buy rating, indicating positive investor sentiment and confidence in the company's future performance.
Target Price: The target price for Praxis Precision Medicines is set at $815, suggesting significant potential for growth based on current market evaluations.
See More
Praxis Precision Medicines Reports Promising Drug Results
- Clinical Trial Results: Praxis Precision Medicines reported a 77% placebo-adjusted seizure reduction for elsunersen in the EMBRAVE Part A trial, indicating significant efficacy in treating early-onset SCN2A developmental and epileptic encephalopathy.
- Positive Patient Response: 57% of patients remained seizure-free for at least 28 days post-treatment, and results were sustained for up to one year in the open-label extension, demonstrating the drug's long-term efficacy and safety.
- Good Safety Profile: No severe drug-related adverse events were reported during the trial, with most treatment-emergent adverse events being mild to moderate, indicating a high safety profile for the drug.
- Positive Market Reaction: Following the promising trial results, Praxis Precision Medicines saw its stock rise approximately 5% in premarket trading, reflecting investor optimism about the company's future prospects.
See More
Praxis Receives FDA Priority Review for Relutrigine
- FDA Review Progress: Praxis Precision Medicines announced that its New Drug Application (NDA) has been accepted for priority review by the FDA, with a target action date of September 27, 2026, marking a significant milestone in the company's evolution towards commercialization, as approval would make it the first disease-modifying therapy for SCN2A and SCN8A developmental epileptic encephalopathies.
- Clinical Trial Results: The NDA is supported by positive results from the EMBOLD study, which was stopped early for efficacy, demonstrating significant therapeutic effects of relutrigine in patients with severe epilepsy, potentially improving their quality of life.
- Drug Designations: Relutrigine has received Orphan Drug, Rare Pediatric Disease, and Breakthrough Therapy designations from the FDA, and if approved, it will be eligible for a Pediatric Review Voucher, enhancing its competitive position in the market.
- Future Research Plans: The drug is also being investigated in the EMERALD trial for broader DEEs, expected to be completed by the end of 2026, showcasing Praxis's ongoing innovation and commitment in the epilepsy treatment space.
See More
